Previous Article | Next Article ![]()
Infection and Immunity, February 2002, p. 528-534, Vol. 70, No. 2
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.70.2.528-534.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Oral Science, National Institute of Infectious Diseases, Tokyo 162-8640,1 Periodontology,2 Molecular Cellular Oncology and Microbiology, Tokyo Medical and Dental University, Tokyo 113-8549,3 Department of Microbiology, Nippon Dental University, Tokyo 102-8159,4 Department of Oral Microbiology, Kyushu Dental College, Kitakyushu, Fukuoka 803-8580, Japan5
Received 28 June 2001/ Returned for modification 21 September 2001/ Accepted 16 October 2001
|
|
|---|
|
|
|---|
CDT was first described as a distinct and novel toxin produced by Escherichia coli (14). The CDTs constitute a family of bacterial heat-labile toxins produced by several bacterial species, including Haemophilus ducreyi, Campylobacter species, Shigella dysenteriae, and Helicobacter hepaticus (23). CDT is encoded by three genes, designated cdtA, cdtB, and cdtC. These three genes encode the polypeptides CdtA (27 kDa), CdtB (29 kDa), and CdtC (20 kDa), which are responsible for the toxic activity (22, 25, 33). Recently, we cloned the cdtA, cdtB, and cdtC genes of A. actinomycetemcomitans, constructed an E. coli expression system, and purified the products of these genes, CdtA, CdtB, and CdtC (24).
Exposure of mammalian cells to several DNA-damaging agents evokes a complicated cellular response, including a reversible block in the cell cycle at the G1 and G2/M phases, and induces programmed cell death (11). The cell cycle arrest at the G1 and G2/M phases reflects the fact that mammalian cells need time to repair damaged DNA. After DNA damage, the cell cycle stops at the transition from the G1 phase to the S phase and at the transition from the G2 phase to the M phase, with DNA complements of 2n and 4n, respectively. It has been reported that transitions between different cell cycle phases are regulated at checkpoints controlled by cyclin-dependent kinases (CDKs), which are activated by cyclins (18). Recently, inhibitors of CDKs have been identified (27). There have been many studies of one of these inhibitors, p21CIP1/WAF1, which negates the kinase activities of cyclin-CDK by directly binding to the catalytically active kinase complexes.
Many investigators have reported that CDTs inhibit proliferation of several mammalian cell lines by inducing a block in the G2 phase of the cell cycle. E. coli CDT was found to block the cell cycle of HeLa cells at the G2/M transition by preventing CDK1 protein kinase dephosphorylation and activation (23). Recently, Shenker et al. (26) reported that lymphocytes treated with the CDT from A. actinomycetemcomitans expressed normal cyclin A and B1 levels but reduced levels of CDK1 and that most CDK1 was in an inactive form. Although recent studies of several investigators have indicated that CDT interferes with the cell cycle-dependent dephosphorylation of Cdc1, the catalytic subunit of cyclin B (5, 37), we are not aware of any reports concerning the contribution of CDK inhibitors to induction of G2 cell cycle arrest in mammalian cells treated with CDT.
The present study was undertaken to determine the mechanism by which the CDT from A. actinomycetemcomitans induces G2 cell cycle arrest in B-cell hybridoma cells. Our results show that the CDT from A. actinomycetemcomitans induces cell distension and G2 cell cycle arrest in HeLa cells and B-cell hybridoma cells. Furthermore, G2 cell cycle arrest may be induced by expression of p21CIP1/WAF1 in B-cell hybridoma cells treated with A. actinomycetemcomitans CDT.
|
|
|---|
Preparation of rCDT from A. actinomycetemcomitans.
The pUC119
H vector and CDT-expressing plasmid pUC119
H-YI-PCR3, which contains three open reading frames (cdtA, cdtB, and cdtC), were inserted into E. coli JM109 as described previously (24). An E. coli strain (JM109/pUC119
H-YI-PCR3) which produced recombinant CDT (rCDT) and a control strain (JM109/pUC119
H) were grown in 2x YT medium supplemented with ampicillin (50 µg/ml). To obtain rCDT and a control preparation from extracts of JM109/pUC119
H-YI-PCR3 and JM109/pUC119
H, E. coli strains were grown at 30°C for 3 h, and the proteins were induced by adding 0.2 mM IPTG (isopropyl-ß-D-thiogalactopyranoside). After 4 h of incubation at 30°C, the bacteria were precipitated by centrifugation, resuspended in 10 ml of sterile phosphate-buffered saline, and disrupted with an Ultrasonic processor (Ultrasonic, Misonix, N.Y.). The supernatants were collected after centrifugation and filtered (Minisart; pore size, 0.20 µm; Sartorius, Göttingen, Germany). The growth-inhibitory activity was determined by the cell viability assay as described previously (21). The protein contents of rCDT and a control preparation were determined with a protein assay reagent (Bio-Rad Laboratories, Richmond, Calif.).
Plasmid and transfection. A human p53 mutant (G273H) was a kind gift from B. Vogelstein (The Johns Hopkins Oncology Center, Baltimore, Md.) (16). HS-72 cells were transfected with the human p53 mutant by using Effectene transfection reagent (Qiagen, Hilden, Germany) according to the manufacturers instructions. HS-72 transfectants were selected on the basis of growth in the presence of G418 (1 mg/ml), and individual clones were isolated by limiting dilution.
Cell cycle analysis. The cells were suspended in a hypotonic solution (0.1% Triton X-100, 1 mM Tris-HCl [pH 8.0], 3.4 mM sodium citrate, 0.1 mM EDTA), stained with 5 µg of propidium iodide per ml, and analyzed with a FACScalibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, Calif.) (21). The population of cells in each cell cycle phase was determined by using ModFit LT software (Becton Dickinson Immunocytometry Systems).
Immunoblot analysis. The cells were suspended in a lysis buffer (150 mM NaCl, 50 mM Tris-HCl [pH 8.0], 1% NP-40). A sample (30 µg of protein) was separated on 12.5% polyacrylamide gels containing 0.1% sodium dodecyl sulfate and then electroblotted on polyvinylidine fluoride membranes. For analysis of p53, the cells were suspended in a lysis buffer (5 mM EDTA, 10 mM Tris-HCl [pH 7.4], 1% Triton X-100), and the lysate was separated on 10% polyacrylamide gels containing 0.1% sodium dodecyl sulfate. Immunodetection was performed with an ECL Western blot detection system (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom) according to the manufacturers instructions. Monoclonal anti-p21CIP1/WAF1 antibody (F-5), monoclonal anti-human p53 antibody (Bp53-12), and polyclonal anti-p53 antibody (PAb240) were purchased from Santa Cruz Biotechnology (Santa Cruz, Calif.). The protein contents of samples were determined with a protein assay reagent (Bio-Rad Laboratories). Blots were stained with Coomassie brilliant blue, and we confirmed that all lanes contained similar amounts of protein extract.
|
|
|---|
H-YI-PCR3) on G2 cell cycle arrest and distension in HS-72 cells. Cultivation with the rCDT (100 µg/ml) increased the population of HS-72 cells in the G2/M phase with time (Fig. 1A and B). As shown in Fig. 1, both HS-72 cells and HeLa cells were distended when they were treated with rCDT (100 µg/ml) for 24 h.
![]() View larger version (71K): [in a new window] |
FIG. 1. Morphology and cell cycle analysis of cells cultured with rCDT from A. actinomycetemcomitans. (A) HS-72 cells cultured with rCDT (100 µg/ml) for 24 h, stained with propidium iodide, and then analyzed with a flow cytometer. CONT, control. (B) DNA contents of the G2/M population in HS-72 cells determined with a flow cytometer at different times. The cells were stimulated with the control preparation (100 µg/ml) (open bars) or rCDT (100 µg/ml) (solid bars). The experiment was performed three times, and similar results were obtained in all experiments. (C to F) HeLa cells (C and D) and HS-72 cells (E and F) cultured with the control preparation (100 µg/ml) (C and E) or rCDT (100 µg/ml) (D and F) for 24 h. Cell morphology was analyzed by phase-contrast microscopy.
|
H) had almost no effect on expression of p21CIP1/WAF1 or p53 at a protein concentration of 100 µg/ml (Fig. 2).
![]() View larger version (25K): [in a new window] |
FIG. 2. p21CIP1/WAF1 and p53 expression in HS-72 cells cultured with rCDT. HS-72 cells were cultured with the control preparation (100 µg/ml) (CONT) or rCDT (100 µg/ml) for different times and analyzed for expression of p21CIP1/WAF1 (A) and p53 (B) by immunoblotting. Monoclonal anti-p21CIP1/WAF1 antibody and polyclonal anti-p53 antibody were used as the primary antibodies to detect p21CIP1/WAF1 and p53, respectively.
|
![]() View larger version (29K): [in a new window] |
FIG. 3. Effect of ectopic expression of E6/E7 on induction of p21CIP1/WAF1 and p53 and G2 cell cycle arrest in HS-72 cells. The cells were cultured with the control preparation (100 µg/ml) (CONT) or rCDT (100 µg/ml) for 18 h. (A) Immunoblot analysis of cell extracts with monoclonal anti-p21CIP1/WAF1 antibody and polyclonal anti-p53 antibody. (B) Flow cytometric analysis of the DNA content of the G2/M population in HS-72 cells stimulated with the control preparation (100 µg/ml) (open bars) or rCDT (100 µg/ml) (solid bars). The experiment was performed three times, and similar results were obtained in all experiments. neoHS-1 and neoHS-2 were control plasmid-transfected clones. E6/E7-HS-1 and E6/E7-HS-3 were human HPV-16 E6/E7-transfected clones.
|
![]() View larger version (34K): [in a new window] |
FIG. 4. Effect of ectopic expression of mutant p53 on induction of p21CIP1/WAF1 and p53 and G2 cell cycle arrest in HS-72 cells. (A) Immunoblot analysis of the cell extract with monoclonal anti-human p-53 antibody to detect expression of mutant p53. (B) The cells were cultured with the control preparation (100 µg/ml) (CONT) or rCDT (100 µg/ml) for 18 h, and an immunoblot analysis of the cell extract was performed with monoclonal anti-p21CIP1/WAF1 antibody. (C) Flow cytometric analysis of the DNA content of the G2/M population in HS-72 cells stimulated with the control preparation (100 µg/ml) (open bars) or rCDT (100 µg/ml) (solid bars). The experiment was performed three times, and similar results were obtained in all experiments. neoHS-14 and neoHS-15 were control plasmid-transfected clones. mt53-HS-1 and mt53-HS-3 were human p53 mutant-transfected clones.
|
![]() View larger version (23K): [in a new window] |
FIG. 5. Effect of rCDT on p21CIP1/WAF1 expression and G2 cell cycle arrest in HeLa cells and COS-1 cells. The cells were cultured with the control preparation (100 µg/ml) (CONT) or rCDT (100 µg/ml) for different times. (A and B) Immunoblot analysis of extracts of COS-1 cells (A) and HeLa cells (B) with monoclonal anti-p21CIP1/WAF1 antibody. (C) Flow cytometric analysis of the DNA content of the G2/M population in COS-1 and HeLa cells stimulated with the control preparation (100 µg/ml) (open bars) or rCDT (100 µg/ml) (solid bars). The experiment was performed three times, and similar results were obtained in all experiments.
|
|
|
|---|
p21CIP1/WAF1 is a well-known negative regulator of CDKs (8, 38, 40). Expression of p21CIP1/WAF1 is regulated by various antimitogenic signals, such as members of the transforming growth factor ß superfamily and p53 (7, 41). Recently, several observations have raised the possibility that p21CIP1/WAF1 plays important roles at several stages in the cell cycle (38). In the present study, we demonstrated that A. actinomycetemcomitans CDT induced G2 cell cycle arrest and enhanced expression of p21CIP1/WAF1 in HS-72 cells, suggesting that p21CIP1/WAF1 is necessary to sustain G2 cell cycle arrest in B-lineage cells. This is consistent with the finding that the p21CIP1/WAF1 protein was expressed in 12-O-tetradecanoylphorbol-13-acetate-treated A549 lung carcinoma cells, which also exhibited G2 cell cycle arrest (35).
We previously reported that in HS-72 cells activins and bone morphogenetic protein 2 (BMP-2) induced G1 arrest and apoptosis, which was associated with accumulation of p21CIP1/WAF1 (13, 40). A recent study indicated that expression of E6/E7 blocked inhibition of retinoblastoma protein (Rb) phosphorylation and G1 cell cycle arrest but did not attenuate apoptotic cell death in BMP-2-treated cells (39). It is well known that E7 protein binds to Rb (8, 20) and that this binding disrupts the interaction between Rb and the E2F transcription factor, allowing E2F to activate its downstream cellular target genes that are required for G1 cell cycle progression (3). In the present study, E6/E7 expression had no effect on expression of p21CIP1/WAF1 or G2 cell cycle arrest in CDT-stimulated cells. These findings are consistent with results showing that BMP-2-induced p21CIP1/WAF1 expression was not blocked in E6/E7-transfected HS-72 cells and had no effect on apoptotic cell death mediated by BMP-2 (39). Although Tchou et al. reported that 12-O-tetradecanoylphorbol-13-acetate-induced growth arrest in A549 cells was associated with induction of p21CIP1/WAF1 (35), further work is needed to elucidate the precise role of p21CIP1/WAF1 in induction of G2 cell cycle arrest in HS-72 cells stimulated with the CDT from A. actinomycetemcomitans.
Recently, it has been reported that activation of endogenous p53 by E7 can be reversed by simultaneous expression of E6 and that HS-72 cells express wild-type p53 mRNA and a very low level of p53 protein (39). In the present study, we found that ectopic expression of human E6/E7 eliminated CDT-induced expression of p53 (Fig. 3A). Song et al. (32) demonstrated that both E6, which inhibits p53 functions, and E7, which inhibits Rb phosphorylation, can also eliminate growth arrest in rodent cells. They also reported that no p53-positive cells were observed in E6 transgenic mice, suggesting that E6 may lead to efficient degradation of p53 (32). Taken together, these findings suggest that activation of endogenous p53 may be regulated by E6 and that overexpressed E6 in E6/E7-transfected HS-72 cells may degrade p53 protein.
p21CIP1/WAF1 is a universal CDK inhibitor, and p21CIP1/WAF1 gene expression is directly regulated by the p53 tumor suppressor protein (9). Bunz et al. (2) demonstrated that p53 and p21CIP1/WAF1 appear to be essential for maintaining the G2 checkpoint in human cells. It has been reported that p21CIP1/WAF1 can be regulated by p53-dependent or -independent pathways in several situations, including during normal tissue development, following serum stimulation, and in the cellular response to several stimulants (19, 41). It has been reported that a human p53 mutant (G273H) blocks normal p53 function (16, 28). In the present study, we examined the abilities of a human p53 mutant (G273H) in HS-72 cells stimulated with CDT from A. actinomycetemcomitans in order to determine the effect of p53 on induction of p21CIP1/WAF1 and G2 cell cycle arrest. As shown in Fig. 4, human dominant negative mutant p53-transfected HS-72 cells expressed p21CIP1/WAF1 protein, even when the cells were cultured with CDT. Furthermore, the dominant negative human mutant p53 had no effect on induction of G2 cell cycle arrest in CDT-stimulated HS-72 cells. These results suggest that p21CIP1/WAF1 expression and G2 cell cycle arrest in HS-72 cells stimulated with CDT may be regulated by p53-independent pathways.
In summary, our results indicate that CDT-induced p21CIP1/WAF1 promotes G2 cell cycle arrest in several types of mammalian cells, such as B-lineage cells and fibroblast-like cells. A. actinomycetemcomitans has been associated with not only periodontitis but also systemic infections in humans, such as endocarditis, pericarditis, meningitis, osteomyelitis, empyema, and subcutaneous abscesses. Our results might provide insight into the important pathological roles of the toxin from A. actinomycetemcomitans in the initiation and progression of severe systemic infectious diseases, as well as progressive periodontitis.
|
|
|---|
|
|
|---|
-irradiation induces a G2 arrest-dependent immunoglobulin
light chain gene expression. EMBO J. 14:13921401.[Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»